myNEO Therapeutics

myNEO Therapeutics is a biotechnology company headquartered in Ghent, Belgium, specializing in AI-powered immunotherapy discovery. Built around its proprietary ImmunoEngine platform, myNEO combines deep immunology expertise with artificial intelligence to decode the immune system at scale — enabling the development of safer, more effective immune-based therapies.

The company's modular platform spans the full discovery pipeline, from antigen identification and target prioritization to drug design and construct optimization. Its suite of AI-driven tools addresses a wide range of therapeutic areas, including oncology (personalized neoantigen discovery), infectious disease, autoimmune disorders, and biologics development. Key capabilities include epitope immunogenicity prediction, surfaceome target identification, codon optimization, and anti-drug antibody risk assessment.